PharVision Advisers’s Valvoline VVV Stock Holding History

PharVision Advisers’s Portfolio VVV Stock Details VVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,360	Closed	-$446K	–	645
2025 Q4	$446K	Buy	+15,360	New	+$493K	0.23%	73

Other funds holding VVV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $7.03B AUM 11.68% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return

PharVision Advisers's VVV Position: Q1 2026 in Review

PharVision Advisers sold out of Valvoline (VVV) in Q1 2026, closing a stake of 15,360 shares — an estimated $446K sold.

PharVision Advisers first reported a position in VVV in Q4 2025 and held it in 1 quarter. The position peaked at $446K in Q4 2025. 417 funds tracked by Wall St. Rank hold VVV as of Q1 2026.

PharVision Advisers reported no remaining Valvoline position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 15,360 Valvoline shares in Q1 2026, an estimated $446K.
PharVision Advisers first reported a position in Valvoline in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Valvoline position peaked at $446K in Q4 2025.
417 funds tracked by Wall St. Rank held Valvoline as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.